LymphoTrack® Dx Assays

This news was updated in April 2024

Invivoscribe’s  NGS LymphoTrack^® Dx Assays are used to detect clonal gene rearrangements, somatic hypermutations and for the study of measurable residual disease (MRD). The full clonality suite of LymphoTrack^® Dx Assays are CE-marked and developed for use with the leading NGS platforms, including optimized multiplex PCR master mixes with primers incorporating platform-specific adapters and specimen tracking sequencing identification tags for a one-step PCR workflow. A comprehensive bioinformatics software package is provided free of charge with purchase; enabling you to identify the DNA sequence, clonal prevalence, V-J family identity for each gene rearrangement, and with the IGHV Leader or IGH FR1 assay, the extent of IGHV somatic hypermutation (SHM).

Key benefits of LymphoTrack® Dx Assays

• Common sources of DNA – Formalin-fixed paraffin-embedded (FFPE), fresh/frozen tissue, peripheral blood, bone marrow
• One-Step PCR Master Mixes
• Multiplexing – Reduces Costs by Combining:
  • Multiple Samples – up to 12 (Ion S5/PGM™) & 24 (MiSeq^®)
  • Multiple Invivoscribe Assays – up to 72 or 168 Samples
  • Other Platform-Specific Assays
• Unparalleled Sensitivity
  • Unparalleled clonality detection with the ability to identify and track the specific sequence of clonal populations for MRD research studies. 
• Analysis Software Package – Included

Simple workflow

Multiplexing capabilities

• Kits include up to 24 indices to increase workflow flexibility
• Designed with the ability to pool multiple targets in a single sequencing run
• Decreased testing costs
• ​Increased throughput capabilities

LymphoTrack Dx software

• Included with each LymphoTrack^® Dx kit
• Available for both Ion Torrent S5/PGM™ and Illumina^® MiSeq^®  platforms
• Does not require bioinformatics personnel
• Can run on most standard Windows platforms
• Utilizes FASTQ files
• Fast results reported in individual PDF reports or in Excel

Data interpretation

• Easy clinical interpretation for the evidence of clonality
• DNA sequence, frequency, length, and family directly revealed
• Somatic Hypermutation status calculated from IGHV sequencing data
• Backed by clinical studies
• Clonal sequences can be tracked in subsequent samples

LymphoTrack® Dx Assays for the Illumina MiSeq®

• LymphoTrack Dx IGH FR1/2/3 Assay – MiSeq
• LymphoTrack Dx IGHV Leader Somatic Hypermutation Assay – MiSeq
• LymphoTrack Dx IGK Assay – MiSeq
• LymphoTrack Dx TRB Assay – MiSeq
• LymphoTrack Dx TRG Assay – MiSeq

LymphoTrack® Dx Assays for the Ion S5™/PGM™

• LymphoTrack Dx IGH FR1/2/3 Assay – S5/PGM
• LymphoTrack Dx IGK Assay – S5/PGM
• LymphoTrack Dx TRG Assay – S5/PGM

References

• Stamatopoulos B, Timbs A, Bruce D, et al. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. Leukemia. 2017;31(4):837-845.
• Shin S, Hwang IS, Kim J, Lee KA, Lee ST, Choi JR. Detection of immunoglobulin heavy chain gene clonality by next-generation sequencing for minimal residual disease monitoring in b-lymphoblastic leukemia. Ann Lab Med. 2017;37(4):331-335.
• Lamarche C, Orio J, Georges-Tobar V, et al. Clinical-scale rapid autologous bk virus-specific t cell line generation from kidney transplant recipients with active viremia for adoptive immunotherapy. Transplantation. 2017;101(11):2713-2721.
• Levy-Mendelovich S, Lev A, Rechavi E, et al. T and B cell clonal expansion in Ras-associated lymphoproliferative disease (Rald) as revealed by next-generation sequencing. Clin Exp Immunol. 2017;189(3):310-317.